Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings plc, a developer of novel oncology immunotherapies, has entered into an exclusive agreement with a major international biotechnology company to evaluate one of its investigational anti-glycan monoclonal antibodies. The antibody, developed through Scancell’s proprietary GlyMab platform, comes with a seven-month exclusivity period and a $1M payment for the evaluation. This collaboration signifies further industry recognition of Scancell’s innovative approach to creating potential cancer treatments.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
